PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go:
Stretch
investment:
Withheld
Incorporated in Luxembourg in July 2018, Glu is a friendly, free-to-use community where users can explore the 'cryptoverse'. Glu is the 'TripAdvisor' for cryptocurrencies or the 'Money Super Market' of crypto exchanges. It serves as a guide to its users through a world full of jargon, mistrust and disjointed information about cryptocurrencies. Glu is working on an integrated B2B & B2C strategy for revenue. It aims to develop B2B customers and build website traffic and then focus on B2C revenues. 41% of the proceeds will be used for product development, 26% for Operations and Customer Support, 17% for Sales and Marketing, and 16% for G&A.
days to go:
Expired
investment:
£158,319
The Studio enable members to achieve results through sustainable, structured training. The Studio offer a whole range of sessions such as group classes, one-to-one personal training, spinning and yoga.
days to go:
Expired
investment:
£30,564
Appital is an emerging financial market platform that will use digital profiling, unique algorithms and notifications to connect institutional demand and supply. With Appital, corporate and institutional companies within the equity capital markets space will have the opportunity to exchange illiquid equity without an investment bank or broker. Appital will also remove the dependence on email and phone, thereby ensuring efficiency and accessibility. The company is raising fund to built the Appital software, achieve FCA regulation, generate marketing material and gain contracts with partner settlement and KYC providers. Furthermore, the company will enhance the functionality of the software by leveraging its network to other products such as primary debt and primary equity deal flow.
days to go:
Expired
investment:
£349,060
JobLab is a candidate-first online job portal that aims to revolutionise recruitment for candidates and employers. JobLab has introduced an innovative way to easily connect graduate talent with meaningful careers. With JobLab, employers find and hire genuine talent efficiently, without the necessity for an agent, thus helping graduates get noticed quickly. One of the most remarkable features of JobLab is the JobLab Tokens that rewards users for their attention and data. Moreover, the company's response rate is now five times better than its competitor, LinkedIn. JobLab, in 2018, saw an annual growth of 240% and generated £240k revenue in Feb 2019. Moreover, the platform has attracted 30,000+ job-seekers and has developed an efficient revenue engine.
days to go:
Expired
investment:
£302,960
Gendius is a company that aims to bring pharmaceuticals and health economics, through clinical research and evidence, to the mobile health market. Their latest innovation, Intellin, is an intelligent remote management diabetes platform, with over 140,000 downloads so far. The COVID-19 crisis has highlighted the need for remote home monitoring of patients, and the company feels that its product is a suitable contender in this domain. Intellin has a reliable connection to over 150 medical devices and apps, and also consists of a two-way communication setup with a healthcare professional via a secure dashboard. Gendius is registered as an approved vendor with AstraZeneca in Saudi Arabia and looks to establish deeper relations with the National Health Service (UK) to create a demand for its product. The company will use the investment to scale its business globally, drive commercialisation, offer an opportunity to its stakeholders, and target venture capital.
days to go:
Expired
investment:
£386,829
Vercida aims to be Europe's largest diversity and inclusion-focused careers website. Vercida's AI integrated system offers candidates with more reliable search results and job matches based on what they truly want from a workplace. The company has drawn 2 million+ visits from 136 countries, has strong comeback rates from high profile clients like Virgin and Home Office, and has won multiple awards. Vercida is driving innovation backed by technology to set new standards to attract, progress, and retain the best candidates for the job.
days to go:
Expired
investment:
£315,220
